bioAffinity Technologies, Inc. released a case study on March 19, 2025, demonstrating CyPath® Lung's ability to identify a hidden recurrence of breast cancer. The case involved an 80-year-old high-risk patient with indeterminate lung nodules on a routine CT scan.
The CyPath® Lung test provided a 'likely malignant' result, which prompted further diagnostic investigation. This led to a follow-up mammogram that revealed a new breast cancer, subsequently confirmed by biopsy.
This case exemplifies CyPath® Lung's potential role beyond primary lung cancer diagnostics, aiding in broader oncological decision-making. An economic impact study cited by the company found that adding CyPath® Lung to standard care could save an average of $2,773 per Medicare patient and $6,460 per private-payer patient annually by reducing unnecessary invasive procedures and follow-up assessments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.